

# A Prospective Study of Serial Outpatient Aquapheresis Ultrafiltration


AT THE CHRIST HOSPITAL IN CINCINNATI, OH<sup>1</sup>



HEART FAILURE  
OUTPATIENT

A prospective, single center study of 23 patients treated with the Aquadex FlexFlow<sup>®</sup> System to manage heart failure (HF) related fluid overload in an **outpatient setting**

## RESULTS:



### 50% DECREASE IN MEDIAN HOSPITAL ADMISSION RATES

- **6 months prior** to outpatient therapy = **2 admissions**
- **6 months after** outpatient therapy = **1 admission**



### 69% DECREASE IN HOSPITALIZATION DAYS

- **Before** outpatient therapy = **16 days**
- **After** outpatient therapy = **5 days**

## PATIENT SELECTION AND TREATMENT:

- Patient selection was **based on rapid re-accumulation of volume** after discharge from the hospital for decompensated heart failure
- Typical treatment duration was up to **8 hours**

## CONCLUSIONS:

- Aquadex<sup>®</sup> treatment as a regularly scheduled outpatient therapy **showed significant reductions (p=0.049) in total number of hospital days** with a trend toward a statistically significant decrease (p=0.091) in number of hospitalizations
- With appropriate patient selection, **outpatient Aquadex therapy may be an additional therapeutic option** for patients with chronic HF and fluid overload plus diuretic resistance

**RX ONLY**

Source: 1. Chung ES, O'Brien TM et al. *Korean Circ J*. 2014; 44(3): 151-61.

**INDICATION:** The Aquadex FlexFlow System is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy; and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies.